{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009109","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.682817+00:00","generated_at":"2026-06-17T14:18:46.861722+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Interpace Biosciences Q4 revenue $8.3M (-9% YoY); FY revenue $31.8M (-4%); loss narrows","bullets":["Q4 net revenue $8.3M, down 9% from $9.1M; operating income $0.1M vs loss of $1.4M prior year.","Full year net revenue $31.8M, down 4% due to ThyGeNEXT reimbursement decline ($3.6M impact).","Full year loss from continuing ops improved to $(5.9)M from $(7.0)M; adjusted EBITDA $(1.2)M vs $(2.0)M.","Cash balance $4.8M at Dec 31, 2022, up from $2.9M at Dec 31, 2021.","Management cites expense reductions and volume growth partially offsetting price headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009109","json":"https://secwatch.observer/filing/0001493152-23-009109.json","markdown":"https://secwatch.observer/filing/0001493152-23-009109.md","text":"https://secwatch.observer/filing/0001493152-23-009109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/0001493152-23-009109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:18:46.861722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6e3bfb7b549ef84e88bb983b564d5ec33e30a09","claim":"INTERPACE BIOSCIENCES, INC. reported the fiscal year ended December 31, 2022 results: revenue $31.8 million.","evidence_excerpt":"Net Revenue was $31.8 million for 2022, a 4% decrease over the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/0001493152-23-009109-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$31.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ca6cc2c375fd82f9c64550abab60fd054cfa14f0","claim":"INTERPACE BIOSCIENCES, INC. reported the fourth quarter ended December 31, 2022 results: revenue $8.3 million.","evidence_excerpt":"Net Revenue was $8.3 million, a decrease of 9% from $9.1 million for the prior year quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/0001493152-23-009109-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$8.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}